Narrow subset of cells is responsible for metastasis in multiple myeloma, study finds
The study suggests that attacking those subsets with targeted drugs may degrade the disease's ability to spread throughout the bone marrow of affected patients, the authors say.
The discovery was made by developing a mouse model of the disease that enabled researchers to track which of 15 genetic groups – or subclones – of myeloma cells spread beyond their initial site in the animals' hind legs. By labeling the different subgroups with fluorescent dyes, researchers determined that just one of the subclones was responsible for the disease metastasis.
They then compared the pattern of gene abnormalities in the initial myeloma tissue and the metastatic tumors. They found that 238 genes were significantly less active in the latter group – comprising a gene “signature” of metastatic myeloma.
“Out of all the genes that were differently expressed in the two groups, we found 11 that played a functional role in metastasis and therefore may be drivers of the disease,” said Irene Ghobrial, MD, of Dana-Farber, the study's senior author. If future studies confirm that role, the genes may become targets for therapies that block myeloma metastasis, she added.
The lead author of the study is Yuji Mishima, PhD, of Dana-Farber. Co-authors are Michele Moschetta, MD, Salomon Manier, MD, Siobhan Glavey, MD, Michaela Reagan, PhD, Yawara Kawano, MD, PhD, Nikhil Munshi, MD, Kenneth Anderson, MD, and Aldo Roccaro, MD, PhD, of Dana-Farber; Jiantao Shi, PhD, and Winston Hide, PhD, of Harvard School of Public Health; Francois Mercier, MD, and David Scadden, MD, of Massachusetts General Hospital.
This study was supported by the Leukemia & Lymphoma Society (LLS) Specialized Center of Research (SCOR) program.
All latest news from the category: Studies and Analyses
innovations-report maintains a wealth of in-depth studies and analyses from a variety of subject areas including business and finance, medicine and pharmacology, ecology and the environment, energy, communications and media, transportation, work, family and leisure.
Breakthrough brings potential glioblastoma drug into focus
A new class of small molecule drugs, now in phase 1 clinical trials, is the first to target circadian clock proteins, which play a key role in the recurrence and…
Powerful Bragg reflector with ultrahigh refractive index metamaterial
We all look in the mirror at least once a day to see our reflection. Mirrors are used not only in daily life but also in cutting-edge technologies such as…
Casting shadows on solar cells connected in series
In shaded conditions, photovoltaics linked end-to-end experience more power loss than cells running in parallel. Large obstacles, like clouds and buildings, can block sunlight from reaching solar cells, but smaller…